
















frican Journal of Urology (2017) 23, 116–119
African  Journal  of  Urology
Official journal of the Pan African Urological Surgeon’s Association
web page of the journal
www.ees.elsevier.com/afju
www.sciencedirect.com
PH and Prostate Diseases
riginal article
he  effect  on  the  sensitivities  of  PSA  and
SA-age  volume  score  of  IPSS  and  nocturia  in
redicting  positive  prostate  biopsy  findings
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Objective:  The PSA-age volume (PSA-AV) score was calculated by multiplying the age and prostate volume
and then dividing the total by the prebiopsy PSA level. The aim of this study was to evaluate the effect on
the sensitivities of PSA and PSA-AV score of International Prostate Symptom Score (I-PSS) and nocturia
in predicting positive prostate biopsy findings.
Subjects  and  methods:  A total of 1302 biopsies data were divided into two groups according to pres-
ence/absence of nocturia. Of these biopsies, 452 biopsies data with I-PSS were also divided into three groups
according to severity of I-PSS. The sensitivities, specificities, positive and negative predictive values of the
PSA-AV and PSA in all the groups were calculated separately.
Results:  Although the sensitivities of PSA and PSA-AV were similar in the patients with nocturia (94.1%
and 95.8%, respectively), the sensitivity of PSA-AV (99.2%) was higher than PSA (91.8%) in the patients
without nocturia. The sensitivities of PSA in mild, moderate and severe I-PSS group were found to be 100%,
92.9% and 95%, respectively (the sensitivities of PSA-AV were 100%, 94.4% and 88.2%, respectively).
While severity of I-PSS was decreasing, although sensitivity of PSA-AV increased regularly, sensitivity of
PSA was variable.
Conclusions:  All our data shows that if we remove most of the factors which effect PSA such as age, prostate
volume, prostatitis and BPH, we may increase the sensitivity of PSA for predicting positive prostate biopsy.
Further PSA formulas contain of result of some tests (I-PSS, uroflowmetry or postvoiding residue urine) as
well as age and prostate volume should increase the sensitivity and specificity of PSA for detecting prostate
cancer.© 2016 Pan African Urological Surge
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The effect on PSA of IPSS and nocturia 
Introduction
Prostate cancer (PCa) is the second most common cancer and the
fifth most common cause of cancer death worldwide. The age-
adjusted incidence rate of PCa was 104.2 per 100,000 persons in
Australia/New Zealand, 94.1 in Western Europe, 85.6 in Northern
America, however only 8.2 in Eastern Asia [1]. The incidence has
more than doubled since 2000 when only 57 new cases per 100,000
men in Australia were registered in 2000 [2].
The digital rectal exam (DRE) and serum prostate specific antigen
(PSA) are important for PCa screening and early detection pro-
grams, they are considered as standard component [3]. PSA is organ
specific, but not disease specific, thus its use for PCa screening lacks
adequate sensitivity [4]. Therefore, due to the false-positive results
obtained by PSA during screening, some of patients are unfortu-
nately candidate to an unnecessary transrectal ultrasound-guided
prostatic biopsy (TRUSPB), that is an invasive procedure which
can lead to significant morbidity, and even mortality such as sepsis
[5,6]. Recently, various strategies were introduced to improve the
sensitivity and specificity of the PSA. Patel et al. developed a novel
formula named PSA-age volume (PSA-AV) that incorporates age,
prostate volume and PSA level into a single score for prostate cancer
detection [7]. Their aim was to reduce the effect of prostate volume
and age on serum PSA level by using this formula. They suggested
that this formula was useful for predicting positive biopsy findings.
An increasing level of PSA can also been seen in benign prostatic
hyperplasia (BPH) and prostatitis. These diseases can increase Inter-
national Prostate Symptom Score (I-PSS) as well as age and prostate
volume [8].
The purpose of the present retrospective study was to evaluate the
effect on the sensitivities of PSA and PSA-age volume score of IPSS
and nocturia in predicting positive prostate biopsy findings.
Subjects  and  methods
This retrospective study was based on the data of 1408 TRUSPB pro-
cedures performed at our institution between 2005 and 2013. The
indications for performing a TRUSPB were elevated or increas-
ing PSA levels, abnormal DRE findings or a previous abnormal
TRUSPB. The database consisted of variables including age,
prebiopsy PSA level, prostate volume, digital rectal examina-
tion, nocturia and IPSS score (only in 452 patients) information.
TRUSPBs were performed using the LOGIQ machine by the urolo-
gists. The prostate volume was calculated using ultrasonography
during the TRUSPB. The number of biopsy cores (6–12 cores)
was determined by the urologists according to their preference. In
patients with an abnormal DRE or ultrasound findings, additional





Table  1  The mean of age, prostate volume, PSA and PSA-AV of patient
Nocturia (+) (n = 819)
Mean ± SD
Age 65.66 ± 8.46 
Prostate volume 48.67 ± 26.90 
PSA (ng/mL) 10.16 ± 29.68 
PSA-AV 388.91 ± 327.75 
PSA-AV: PAS-age volume.
* P < 0.05 was considered statistically significant.117
id not have complete data, patients who were <40 years or >79
ears old, and patients who had undergone repeat biopsies. A total
f 1302 biopsy specimens were analyzed. The PSA-age volume
PSA-AV) score was calculated by multiplying the age and prostate
olume and then dividing the total by the prebiopsy PSA level [7].
 total of 1302 biopsies data were divided into two groups according
o presence/absence of nocturia. Of these biopsies, 452 biopsies
ata with I-PSS were also divided into three groups according to
everity of I-PSS (mild: 1–7; moderate: 8–19; severe: 20–35). The
ensitivities, specificities, positive and negative predictive values of
he PSA-AV cutoff of 700 and PSA cutoff of 4 ng/mL in all the
roups were calculated separately. Statistical analyses were carried
ut using SPSS 13.0 (SPSS Inc.). P  values < 0.05 were considered
ignificant.
esults
he mean age of the patients in our study was 64.92 ±  8.49
n  = 1302). The mean PSA level, PSA-AV score and mean
rostate volume were 9.98 ±  24.91 ng/mL, 395.71 ±  357.21 and
8.77 ±  26.56 cm3, respectively. Of the 1302 prostate biopsies, 358
iopsy specimens (27.5%) were positive for prostate cancer.
he mean of age, prostate volume, PSA and PSA-AV in the patients
ith and without nocturia were given Table 1. Although the sen-
itivities of PSA and PSA-AV were similar in the patients with
octuria (94.1% and 95.8%, respectively), the sensitivity of PSA-
V (99.2%) was higher than PSA (91.8%) in the patients without
octuria (Table 2).
able 3 shows the mean of age, PSA, PSA-AV and prostate volume
n the three groups that were divided according to I-PSS. The sensi-
ivities of PSA 4 ng/mL in mild, moderate and severe I-PSS group
ere found to be 100%, 92.9% and 95%, respectively (Table 4). The
ensitivities of PSA-AV cutoff of 700 in mild, moderate and severe
-PSS group were 100%, 94.4% and 88.2%, respectively. While
everity of I-PSS was decreasing, although sensitivity of PSA-AV
ncreased regularly, sensitivity of PSA was variable.
iscussion
he use of PSA as a serum marker has revolutionized the diagnosis
f PCa [9]. Although PSA is a highly organ-specific marker, it is not
 cancer-specific marker. Thus, serum levels may be elevated in the
resence of BPH, prostatitis and other non-malignant conditions as
ell as age and prostate volume [10]. PSA-AV was developed by
atel et al. to correct the impact of prostate volume and age on PSA
evels [7]. They noticed that a PSA-AV score of 700 was a useful
ormula for predicting positive biopsy findings in patients with small
s with and without nocturia.
Nocturia (−) (n = 483)
Mean ± SD
P-value
64.18 ± 8.53 0.003*
48.87 ± 26.21 0.877
9.8 ± 20.12 0.683
402.49 ± 372.41 0.537
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Table  2  The sensitivities, specificities, positive and negative predictive values of PSA 4 ng/mL and PSA-AV 700 for predicting positive prostate
biopsy in the patients with and without nocturia.
Nocturia (+) Nocturia (−)
PSA 4 ng/mL PSA-AV 700 PSA 4 ng/mL PSA-AV 700
Sensitivity (%) 94.1 95.8 91.8 99.2
Specificity (%) 16.5 13.7 15.8 11.6
PPV (%) 31.3 31.0 26.9 27.5
NPV (%) 87.3 88.9 85.1 97.7
PSA-AV: PSA-age volume, PPV: positive predictive value, NPV: negative predictive value.
Table  3  The mean of age, PSA, PSA-AV and prostate volume in the three groups that were divided according to I-PSS.
Mild (n = 88)
Mean ± SD
Moderate (n = 244)
Mean ± SD
Severe (n = 120)
Mean ± SD
P-value
Age 61.46 ± 8.55 63.79 ± 7.46 65.66 ± 8.08 0.009*
Prostate volume 40.95 ± 20.63 48.22 ± 25.00 47.84 ± 19.49 0.225
PSA (ng/mL) 9.40 ± 7.51 13.96 ± 20.36 14.04 ± 23.29 0.262
PSA-AV 396.57 ± 253.48 461.90 ± 340.20 477.61 ± 403.86 0.141
Mild: I-PSS = 1–7, moderate: I-PSS = 8–19, severe: I-PSS = 20–35, PSA-AV: PSA-age-volume.
* P < 0.05 was considered statistically significant.
Table  4  The sensitivities, specificities, positive and negative predictive values of PSA 4 ng/mL and PSA-AV 700 for predicting positive prostate
biopsy in the patients with mild, moderate and severe I-PSS.
Mild (n = 88) Moderate (n = 244) Severe (n = 120)
PSA PSA-AV PSA PSA-AV PSA PSA-AV
Sensitivity (%) 100 100 92.9 94.4 95.0 88.2
Specificity (%) 16.4 8.9 17.4 17.6 10.3 21.3
PPV (%) 21.5 19.0 20.4 19.0 17.9 16.9










































Mild: I-PSS = 1–7, moderate: I-PSS = 8–19, severe: I-PSS = 20–35, PSA-A
PPV: positive predictive value, NPV: negative predictive value.
rostates. Currently, most clinicians recommend a biopsy once a
atient’s serum PSA rises above 4.0 ng/mL. Catalona et al. reported
his PSA level or higher was appropriate as the PSA cutoff value
or the screening of PCa. Since then, this value has been the most
ommonly used clinically [11]. We investigated the sensitivities of
SA and PSA-AV in patients with and without lower urinary tract
ymptoms (LUTS). We found that although the sensitivities of PSA
nd PSA-AV for predicting positive prostate biopsy in the patients
ith nocturia were similar (94.1% and 95.8%, respectively), the
ensitivity of PSA-AV (99.2%) in the patients without nocturia was
igher than the sensitivity of PSA (91.8%). The mean age in the
atients with nocturia were significantly higher than the patients
ithout nocturia (P  = 0.003). Similarly, Patel et al. reported that
SA-AV was a useful formula for predicting positive biopsy findings
n younger patients with small prostates [7].
e also analyzed the sensitivities of PSA and PSA-AV in three
roups that divided according to I-PSS. Our data showed that while
-PSS was decreasing, sensitivity of PSA-AV was rising (Table 4).
owever we did not find any relationship between sensitivity of
SA and I-PSS (Table 4). While I-PSS was decreasing, sensi-
ivity of PSA was variable. This may be the effect of prostate
olume and age on PSA. Because when we minimized this effect by
sing PSA-AV formula, we found a negative correlation between
-PSS severity and sensitivity of PSA-AV. We suggest that PSA-





SA especially in the patients with low I-PSS score and PSA 2.5 to
.0 ng/mL.
ll our data shows that if we remove most of the factors which
ffect PSA such as age, prostate volume, prostatitis and BPH, we
ay increase the sensitivity of PSA for predicting positive prostate
iopsy. PSA-AV removes only the impact of age and prostate volume
n PSA. The other factors (BPH and prostatitis) are evaluated I-PSS,
roflowmetry or postvoiding residue urine. We think that further
SA formulas consist of other factors which may increase in PSA
s well as age and prostate volume may increase the sensitivity and
pecificity of PSA for detecting prostate cancer.
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